Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Giuliani, Anna Lisa ^a   Colognesi, Davide ^a   Ricco, Tiziana ^a   Roncato, Carlotta ^a   Capece, Marina ^a   Amoroso, Francesca ^a   Wang, Qi Guang ^b   De Marchi, Elena ^a   Gartland, Allison ^c   Di Virgilio, Francesco ^a   Adinolfi, Elena ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' (4 BENZOYL) BENZOYL ADENOSINE TRIPHOSPHATE; A 740003; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYCLOSPORIN A; ISOPROTEIN; KI 67 ANTIGEN; NUCLEAR FACTOR OF ACTIVATED T CELLS COMPLEX 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X7 RECEPTOR A; PURINERGIC P2X7 RECEPTOR B; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ARTICLE; BONE MINERALIZATION; BONE REMODELING; CALCIUM MOBILIZATION; CANCER GROWTH; CELL DENSITY; CHANNEL GATING; CHILD; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; GENETIC TRANSFECTION; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TISSUE MICROARRAY; BONE TUMOR; EXTRACELLULAR SPACE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; TUMOR CELL LINE; YOUNG ADULT;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; BONE NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR SPACE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; OSTEOPROTEGERIN; OSTEOSARCOMA; PROTEIN ISOFORMS; RANK LIGAND; RECEPTORS, PURINERGIC P2X7; TRANSFECTION; YOUNG ADULT;

EID: 84907225933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107224     Document Type: Article

References (59)

1. Hameed M, Dorfman H (2011) Primary malignant bone tumors-recent developments. Semin Diagn Pathol 28: 86-101.
2. Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13. 10.1007/978-1-4419-0284-9-1 [doi].
3. Yasuda H (2013) RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop 4: 207-217. 10.5312/wjo.v4.i4.207 [doi].
4. Salinas-Souza C, De OR, Alves MT, Garcia Filho RJ, Petrilli AS, et al. (2013) The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses. Hum Pathol 44: 2188-2198. S0046-8177(13)00183-4 [pii];10.1016/j.humpath.2013.04.013 [doi].
5. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, et al. (2012) Expression of P2X7 Receptor Increases In Vivo Tumor Growth. Cancer Res 72: 2957-2969. 0008-5472.CAN-11-1947 [pii];10.1158/0008-5472.CAN-11-1947 [doi].
6. Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, et al. (2012) Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur J Pharmacol 695: 20-26. S0014-2999(12)00755-8 [pii];10.1016/j.ejphar.2012.09.001 [doi].
7. Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, et al. (2011) P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30: 2108-2122. onc2010593 [pii];10.1038/onc.2010.593 [doi].
8. Jelassi B, Anchelin M, Chamouton J, Cayuela ML, Clarysse L, et al. (2013) Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 34: 1487-1496. bgt099 [pii];10.1093/carcin/bgt099 [doi].
9. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, et al. (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 274: 33206-33208.
10. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, et al. (2005) Basal Activation of the P2X7 ATP Receptor Elevates Mitochondrial Calcium and Potential, Increases Cellular ATP Levels, and Promotes Serum-independent Growth. Mol Biol Cell 16: 3260-3272.
11. Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, et al. (2009) Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 284: 10120-10128.
12. Hill LM, Gavala ML, Lenertz LY, Bertics PJ (2010) Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol 185: 3028-3034. jimmunol.1001298 [pii];10.4049/jimmunol.1001298 [doi].
13. Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, et al. (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24: 3393-3404. fj.09-153601 [pii];10.1096/fj.09-153601 [doi].
14. Di Virgilio F, Ferrari D, Adinolfi E (2009) P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 5: 251-256. 10.1007/s11302-009-9145-3 [doi].
15. Adinolfi E, Amoroso F, Giuliani AL (2012) P2X7 Receptor Function in Bone-Related Cancer. J Osteoporos 2012: 637863. 10.1155/2012/637863 [doi].
16. Panupinthu N, Rogers JT, Zhao L, Solano-Flores LP, Possmayer F, et al. (2008) P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol 181: 859-871. jcb.200708037 [pii];10.1083/jcb.200708037 [doi].
17. Jiang LH, Baldwin JM, Roger S, Baldwin SA (2013) Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms. Front Pharmacol 4: 55. 10.3389/fphar.2013.00055 [doi].
18. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S (2005) Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 332: 17-27.
19. Feng YH, Li X, Wang L, Zhou L, Gorodeski GI (2006) A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem 281: 17228-17237.
20. Gartland A, Hipskind RA, Gallagher JA, Bowler WB (2001) Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res 16: 846-856.
21. Orriss IR, Knight GE, Ranasinghe S, Burnstock G, Arnett TR (2006) Osteoblast responses to nucleotides increase during differentiation. Bone 39: 300-309. S8756-3282(06)00347-4 [pii];10.1016/j.bone.2006.02.063 [doi].
22. Alqallaf SM, Evans BA, Kidd EJ (2009) Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. Br J Pharmacol 156: 1124-1135. BPH119 [pii];10.1111/j.1476-5381.2009.00119.x [doi].
23. Ke HZ, Qi H, Weidema AF, Zhang Q, Panupinthu N, Crawford DT, et al. (2003) Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol 17: 1356-1367.
24. Li J, Liu D, Ke HZ, Duncan RL, Turner CH (2005) The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem 280: 42952-42959.
25. Wesselius A, Bours MJ, Agrawal A, Gartland A, Dagnelie PC, et al. (2012) Role of purinergic receptor polymorphisms in human bone. Front Biosci 17: 2572-2585. 3873 [pii].
26. Ohlendorff SD, Tofteng CL, Jensen JE, Petersen S, Civitelli R, et al. (2007) Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics 17: 555-567. 10.1097/FPC.0b013e3280951625 [doi];01213011-200707000-00010 [pii].
27. Jorgensen NR, Husted LB, Skarratt KK, Stokes L, Tofteng CL, et al. (2012) Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet. ejhg2011253 [pii];10.1038/ejhg.2011.253 [doi].
28. Gartland A, Skarratt KK, Hocking LJ, Parsons C, Stokes L, et al. (2012) Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet 20: 559-564. ejhg2011245 [pii];10.1038/ejhg.2011.245 [doi].
29. Wesselius A, Bours MJ, Henriksen Z, Syberg S, Petersen S, et al. (2013) Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Osteoporos Int 24: 1235-1246. 10.1007/s00198-012-2059-x [doi].
30. Husted LB, Harslof T, Stenkjaer L, Carstens M, Jorgensen NR, et al. (2013) Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis. Osteoporos Int 24: 949-959. 10.1007/s00198-012-2035-5 [doi].
31. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA (2002) Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone 31: 582-590. S8756328202008773 [pii].
32. Gartland A, Buckley KA, Hipskind RA, Bowler WB, Gallagher JA (2003) P2 receptors in bone-modulation of osteoclast formation and activity via P2X7 activation. Crit Rev Eukaryot Gene Expr 13: 237-242.
33. Gartland A, Buckley KA, Bowler WB, Gallagher JA (2003) Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif Tissue Int 73: 361-369.
34. Jorgensen NR, Henriksen Z, Sorensen OH, Eriksen EF, Civitelli R, et al. (2002) Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem 277: 7574-7580.
35. Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ (2009) Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal.
36. Okumura H, Shiba D, Kubo T, Yokoyama T (2008) P2X7 receptor as sensitive flow sensor for ERK activation in osteoblasts. Biochem Biophys Res Commun 372: 486-490. S0006-291X(08)00987-X [pii];10.1016/j.bbrc.2008.05.066 [doi].
37. Liu D, Genetos DC, Shao Y, Geist DJ, Li J, Ke HZ, et al. (2008) Activation of extracellular-signal regulated kinase (ERK1/2) by fluid shear is Ca(2+)- and ATP-dependent in MC3T3-E1 osteoblasts. Bone 42: 644-652.
38. Grol MW, Zelner I, Dixon SJ (2012) P2X-mediated calcium influx triggers a sustained, PI3K-dependent increase in metabolic acid production by osteoblast-like cells. Am J Physiol Endocrinol Metab 302: E561-E575. ajpendo.00209.2011 [pii];10.1152/ajpendo.00209.2011 [doi].
39. Rumney RM, Sunters A, Reilly GC, Gartland A (2012) Application of multiple forms of mechanical loading to human osteoblasts reveals increased ATP release in response to fluid flow in 3D cultures and differential regulation of immediate early genes. J Biomech 45: 549-554. S0021-9290(11)00718-4 [pii];10.1016/j.jbiomech.2011.11.036 [doi].
40. Brandao-Burch A, Key ML, Patel JJ, Arnett TR, Orriss IR (2012) The P2X7 receptor is an important regulator of extracellular ATP levels. Frontiers in Endocrinology 3. 10.3389/fendo.2012.00041.
41. Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, et al. (1998) Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92: 3521-3528.
42. Rhim JS, Putman DL, Arnstein P, Huebner RJ, McAllister RM (1977) Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine. Int J Cancer 19: 505-510.
43. Stern PH (2006) The calcineurin-NFAT pathway and bone: intriguing new findings. Mol Interv 6: 193-196.
44. Monif M, Reid CA, Powell KL, Smart ML, Williams DA (2009) The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 29: 3781-3791.
45. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, et al. (2006) A role for P2X7 in microglial proliferation. J Neurochem 99: 745-758.
46. Slater M, Danieletto S, Pooley M, Cheng TL, Gidley-Baird A, et al. (2004) Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat 83: 1-10.
47. Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA (2004) Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44: 206-215.
48. Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, et al. (2008) Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149: 389-396.
49. Chong JH, Zheng GG, Zhu XF, Guo Y, Wang L, et al. (2010) Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. Biochem Biophys Res Commun 391: 498-504. S0006-291X(09)02264-5 [pii];10.1016/j.bbrc.2009.11.087 [doi].
50. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, et al. (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3: e2599.
51. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, et al. (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577. 334/6062/1573 [pii];10.1126/science.1208347 [doi].
52. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S (2013) Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24: 130-137. S1535-6108(13)00235-3 [pii];10.1016/j.ccr.2013.05.008 [doi].
53. Liu PS, Chen CY (2010) Butyl benzyl phthalate suppresses the ATP-induced cell proliferation in human osteosarcoma HOS cells. Toxicol Appl Pharmacol 244: 308-314. S0041-008X(10)00018-9 [pii];10.1016/j.taap.2010.01.007 [doi].
54. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, et al. (2008) NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118: 3775-3789.
55. Costa-Junior HM, Sarmento VF, Coutinho-Silva R (2011) C terminus of the P2X7 receptor: treasure hunting. Purinergic Signal 7: 7-19. 10.1007/s11302-011-9215-1 [doi].
56. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F (2005) A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 16: 3659-3665.
57. Orriss IR, Key ML, Hajjawi MO, Arnett TR (2013) Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralisation. PLoS One 8: e69057. 10.1371/journal.pone.0069057 [doi];PONE-D-13-14735 [pii].
58. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N (2013) Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 60: 1009-1015. 10.1002/pbc.24429 [doi].
59. Beristain AG, Narala SR, Di Grappa MA, Khokha R (2012) Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci 125: 943-955. jcs.094029 [pii];10.1242/jcs.094029 [doi].